Here's a Quick Look Into AbbVie Stock

AbbVie marked a 1.0% change today, compared to 0.5% for the S&P 500. Is it a good value at today's price of $144.41? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.

  • AbbVie belongs to the Healthcare sector, which has an average price to earnings (P/E) ratio of 13.21 and an average price to book (P/B) of 4.07

  • The company's P/B ratio is 19.5

  • AbbVie has a trailing 12 month Price to Earnings (P/E) ratio of 49.6 based on its trailing 12 month price to earnings (Eps) of $2.91 per share

  • Its forward P/E ratio is 10.4 is, based on its 12 month price to earnings (Eps) is $2.91

  • ABBV has a Price to Earnings Growth ratio of 63.35, which shows the company is overvalued when we factor growth into the price to earnings calculus.

  • Over the last four years, AbbVie has averaged free cash flows of $16,085,250,000.00, which on average grew 20.8%

  • ABBV's gross profit margins have averaged 73.1 % over the last four years and during this time they had a growth rate of -3.1 % and a coefficient of variability of 6.2 %.

  • ABBV has an average analyst rating of buy and is -11.21% away from its mean target price of $162.65 per share

At Market Interference, we believe in giving retail investors access to timely and accurate data to help inform their investment decisions. subscribe to our free newsletter today to keep track of each day's market movers!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.